Medical devices industry M&A deals in November 2019 total $5.78bn globally

19 December 2019 (Last Updated December 19th, 2019 06:18)

Medical devices industry M&A deals in November 2019 total $5.78bn globally

Total medical devices industry M&A deals in November 2019 worth $5.78bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 4140.4% over the previous month and a rise of 53.1% when compared with the last 12-month average, which stood at $3.77bn.

Comparing deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $5.4bn. At the country level, The Netherlands topped the list in terms of deal value at $5.4bn.

In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of M&A deals activity in November 2019 was the US with 11 deals, followed by Switzerland with four and The Netherlands with two.

In 2019, as of the end of November 2019, medical devices M&A deals worth $37.49bn were announced globally, marking an increase of 3.5% year on year.

Medical devices industry M&A deals in November 2019: Top deals

The top five medical devices industry M&A deals accounted for 99.9% of the overall value during November 2019.

The combined value of the top five medical devices M&A deals stood at $5.77bn, against the overall value of $5.78bn recorded for the month.

The top five medical devices industry deals of November 2019 tracked by GlobalData were:

1) Stryker’s $5.4bn acquisition of Wright Medical Group

2) The $187m acquisition of Plastique and Thermoform Engineered Quality by Sonoco Products

3) Dare Bioscience’s $101.5m acquisition of Keratin Biosciences

4) The $75m acquisition of Pursuit Vascular by ICU Medical

5) Mitsubishi Chemical Performance Polymers’ asset transaction with AdvanSource Biomaterials for $7.25m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.